Published in J Clin Oncol on May 15, 2004
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood (2007) 3.32
Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis (2014) 2.07
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood (2010) 1.67
Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev (2007) 1.49
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov (2012) 1.40
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med (2005) 1.33
M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One (2011) 1.24
Venous thromboembolic disease and cancer. Postgrad Med J (2006) 1.23
Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol (2009) 1.11
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost (2006) 1.09
Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol (2007) 1.07
Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med (2008) 1.03
Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res (2013) 0.98
Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol (2010) 0.98
FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer (2009) 0.98
Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood (2013) 0.97
ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis (2005) 0.95
Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS (2010) 0.94
Stroke and Cancer- A Complicated Relationship. J Neurol Transl Neurosci (2015) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer (2009) 0.90
Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res (2008) 0.89
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol (2014) 0.88
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol (2008) 0.87
The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol (2010) 0.87
Primary prevention of venous thromboembolism in medical and surgical oncology patients. Br J Cancer (2010) 0.86
Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer (2010) 0.85
Effect of anti-fibrinolytic therapy on experimental melanoma metastasis. Clin Exp Metastasis (2008) 0.85
Thromboembolic disease in patients with high-grade glioma. Neuro Oncol (2012) 0.85
Protease-activated receptors in cancer: A systematic review. Oncol Lett (2011) 0.85
Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Relat Outcome Meas (2011) 0.85
Venous gangrene and cancer: a cool look at a burning issue. Int Semin Surg Oncol (2007) 0.84
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer (2009) 0.84
Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity. PLoS One (2013) 0.84
Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol (2014) 0.83
The risk of a second cancer after hospitalisation for venous thromboembolism. Br J Cancer (2005) 0.83
Evidence-based guidance on venous thromboembolism in patients with solid tumours. Curr Oncol (2014) 0.83
Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer (2007) 0.82
Regulating surgical oncotaxis to improve the outcomes in cancer patients. Surg Today (2013) 0.82
Amino acid substitutions in the E2 glycoprotein of Sindbis-like virus XJ-160 confer the ability to undergo heparan sulfate-dependent infection of mouse embryonic fibroblasts. Virol J (2010) 0.82
Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation. J Cell Mol Med (2007) 0.82
Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clin Exp Metastasis (2008) 0.82
Erythropoietin update 2011. Med Sci Monit (2011) 0.82
Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer (2008) 0.82
Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence. Br J Cancer (2006) 0.81
Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer (2006) 0.81
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol (2009) 0.81
Pulmonary Venous Obstruction in Cancer Patients. J Oncol (2015) 0.81
What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg (2012) 0.81
Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol (2015) 0.81
Cancer and thrombosis: an increasingly important association. Support Care Cancer (2008) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res (2008) 0.79
Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol (2015) 0.79
Thrombin expression in prostate: a novel finding. Cancer Invest (2011) 0.78
Primary prevention of venous thromboembolism in elderly medical patients. Clin Interv Aging (2008) 0.78
The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2014) 0.77
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer (2011) 0.77
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis (2011) 0.77
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br J Cancer (2010) 0.76
Haemophilia and cancer: a personal perspective. Blood Transfus (2012) 0.76
Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. J Cancer Res Clin Oncol (2016) 0.76
Treatment of mobile right heart thrombi with low-molecular-weight heparin. BMJ Case Rep (2013) 0.76
Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer. Yonsei Med J (2013) 0.76
Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells. Oncol Lett (2010) 0.75
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget (2016) 0.75
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open (2016) 0.75
Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model. Cancer Res Treat (2009) 0.75
Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells. Cancer Biol Ther (2013) 0.75
A systematic review of Cochrane anticoagulation reviews. Medscape J Med (2009) 0.75
Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. BMC Res Notes (2012) 0.75
The antineoplastic effect of low-molecular-weight heparins - a literature review. Contemp Oncol (Pozn) (2013) 0.75
Management of cancer-associated venous thrombosis. Vasc Health Risk Manag (2006) 0.75
Prophylactic heparin in palliative care: ...to a challenging idea. BMJ (2006) 0.75
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 0.75
Inhibition of osteolytic bone metastasis by unfractionated heparin. Clin Exp Metastasis (2008) 0.75
Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers. World J Gastrointest Oncol (2017) 0.75
[Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy]. Urologe A (2017) 0.75
Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway. Oncotarget (2017) 0.75
Thromboembolic disease in cancer patients. Support Care Cancer (2013) 0.75
Thromboprophylaxis in patients receiving inpatient palliative care: a survey of present practice in Austria. Support Care Cancer (2011) 0.75
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94
Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (2010) 4.63
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol (2012) 4.30
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology (2002) 2.92
Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med (2009) 2.88
Beyond the development of quality-of-life instruments: where do we go from here? J Clin Oncol (2002) 2.81
Venous thromboembolism and cancer: risks and outcomes. Circulation (2003) 2.68
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem (2001) 2.47
SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Bioinformatics (2008) 2.40
BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol Cell (2004) 2.32
Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas cancer surgery in two Canadian Provinces. Ann Surg Oncol (2010) 2.16
Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol (2002) 2.10
Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol (2002) 2.08
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol (2011) 2.06
Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol (2004) 2.01
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion (2002) 1.98
The importance of reporting patient recruitment details in phase III trials. J Clin Oncol (2006) 1.92
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.88
Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl (2007) 1.87
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol (2003) 1.83
Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol (2004) 1.80
Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol (2009) 1.77
Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol (2006) 1.70
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer (2004) 1.68
Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol (2006) 1.67
Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene (2002) 1.67
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer (2010) 1.66
Harvesting waste thermal energy using a carbon-nanotube-based thermo-electrochemical cell. Nano Lett (2010) 1.63
Long-term results of distal pancreatectomy for chronic pancreatitis in 90 patients. Ann Surg (2002) 1.62
Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol (2004) 1.61
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology (2005) 1.61
Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. J Clin Oncol (2012) 1.58
Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics (2007) 1.56
Funding oncology clinical trials: are cooperative group trials sustainable? J Clin Oncol (2012) 1.56
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol (2012) 1.55
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res (2004) 1.54
A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol (2004) 1.54
Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol (2013) 1.54
Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun (2002) 1.54
HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer (2004) 1.48
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res (2012) 1.47
SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). Nucleic Acids Res (2012) 1.45
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res (2005) 1.44
Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene (2004) 1.43
Using BioMart as a framework to manage and query pancreatic cancer data. Database (Oxford) (2011) 1.43
S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res (2004) 1.41
Implications of the 2013 U.S. Veterinary Workforce Study and recommendations for future actions: AVMA Workforce Advisory Group. J Am Vet Med Assoc (2013) 1.39
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
Outcome of Copeland surface replacement shoulder arthroplasty. J Shoulder Elbow Surg (2005) 1.38
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res (2007) 1.33
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. J Antimicrob Chemother (2005) 1.27
AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res (2011) 1.26
Registries that show efficacy: good, but not good enough. J Clin Oncol (2008) 1.25
Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. Radiographics (2009) 1.25
Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal (2007) 1.24
Management of delayed postoperative hemorrhage after pancreaticoduodenectomy: a meta-analysis. Arch Surg (2008) 1.22
Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res (2005) 1.22
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol (2003) 1.19
Online resources of cancer data: barriers, benefits and lessons. Brief Bioinform (2010) 1.19
Interactive workshops increase chlamydia testing in primary care--a controlled study. Fam Pract (2008) 1.19
What can developmental disorders tell us about the neurocomputational constraints that shape development? The case of Williams syndrome. Dev Psychopathol (2003) 1.18
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res (2013) 1.17
Mechanism of ion permeation and selectivity in a voltage gated sodium channel. J Am Chem Soc (2012) 1.17
Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol (2011) 1.17
Exploring the Williams syndrome face-processing debate: the importance of building developmental trajectories. J Child Psychol Psychiatry (2004) 1.16
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol (2005) 1.15
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics (2003) 1.14
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol (2010) 1.12
Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle (2007) 1.11
Adjuvant chemotherapy for breast cancer--30 years later. N Engl J Med (2006) 1.09
The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res (2007) 1.09
Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther (2004) 1.08
Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity (2006) 1.08
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene (2005) 1.06
EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer (2012) 1.05
The Pancreatic Expression database: 2011 update. Nucleic Acids Res (2010) 1.04
Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proteomics Clin Appl (2008) 1.03
Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene (2003) 1.02
Surgical intervention for pulmonary metastases. Dtsch Arztebl Int (2012) 1.02